Skip to main content
Top
Published in: Annals of Surgical Oncology 2/2021

Open Access 01-02-2021 | Pancreatic Tumors

Staging the Tumor and Staging the Host: Pretreatment Combined Neutrophil Lymphocyte Ratio and Modified Glasgow Prognostic Score Is Associated with Overall Survival in Patients with Esophagogastric Cancers Undergoing Treatment with Curative Intent

Authors: Stephen T. McSorley, PhD, MRCS, Hiu Y. N. Lau, BSc, David McIntosh, FRCP, Matthew J. Forshaw, FRCS, Donald C. McMillan, PhD, Andrew B. Crumley, MD, FRCS

Published in: Annals of Surgical Oncology | Issue 2/2021

Login to get access

Abstract

Background

This study examined whether an innate systemic inflammatory response (SIR) measured by combination neutrophil to lymphocyte ratio (NLR) and modified Glasgow Prognostic Score (mGPS) was associated with overall survival (OS) in patients with esophagogastric cancer (EC) undergoing neoadjuvant chemotherapy (NAC) followed by surgery.

Methods

Patients diagnosed with EC, managed with NAC prior to surgery at a regional referral center, between January 2010 and December 2015, were included. The mGPS and NLR were calculated within 12 weeks before NAC. Patients were grouped by combined NLR/mGPS score into three groups of increasing SIR: NLR ≤ 3 (n = 152), NLR > 3 + mGPS = 0 (n = 55), and NLR > 3 + mGPS > 0 (n = 32). Univariable and multivariable Cox regression was used to analyse OS.

Results

Overall, 337 NAC patients were included, with 301 (89%) proceeding to surgery and 215 (64%) having R0 resection. There were 203 deaths, with a median follow-up of those alive at censor of 69 months (range 44–114). Higher combined NLR/mGPS score (n = 239) was associated with poorer OS independent of clinical stage and performance status (hazard ratio 1.28, 95% confidence interval 1.02–1.61; p = 0.032), higher rate of progression on NAC (7% vs. 7% vs. 19%; p = 0.003), and lower proportion of eventual resection (80% vs. 84% vs. 53%; p = 0.003).

Conclusions

The combined NLR/mGPS score was associated with OS and initial treatment outcomes in patients undergoing NAC prior to surgery for EC, stratifying survival in addition to clinical staging and performance status. The host SIR may be a useful adjunct to multidisciplinary decision making.
Appendix
Available only for authorised users
Literature
5.
go back to reference Viklund P, Lindblad M, Lu M, Ye W, Johansson J, Lagergren J. Risk factors for complications after esophageal cancer resection. Ann Surg. 2006;243(2):204–11.PubMedPubMedCentral Viklund P, Lindblad M, Lu M, Ye W, Johansson J, Lagergren J. Risk factors for complications after esophageal cancer resection. Ann Surg. 2006;243(2):204–11.PubMedPubMedCentral
7.
go back to reference Knight W, Zylstra J, Van Hemelrijck M et al. Patterns of recurrence in oesophageal cancer following oesophagectomy in the era of neoadjuvant chemotherapy. BJS Open 2017;1(6):182–90.PubMed Knight W, Zylstra J, Van Hemelrijck M et al. Patterns of recurrence in oesophageal cancer following oesophagectomy in the era of neoadjuvant chemotherapy. BJS Open 2017;1(6):182–90.PubMed
8.
go back to reference Crumley A, McMillan D, McKernan M, Going J, Shearer C, Stuart R. An elevated C-reactive protein concentration, prior to surgery, predicts poor cancer-specific survival in patients undergoing resection for gastro-oesophageal cancer. Br J Cancer, 2006;94(11):1568–71.PubMedPubMedCentral Crumley A, McMillan D, McKernan M, Going J, Shearer C, Stuart R. An elevated C-reactive protein concentration, prior to surgery, predicts poor cancer-specific survival in patients undergoing resection for gastro-oesophageal cancer. Br J Cancer, 2006;94(11):1568–71.PubMedPubMedCentral
9.
go back to reference Dutta S, Crumley A, Fullarton G, Horgan P, McMillan D. Comparison of the prognostic value of tumour- and patient-related factors in patients undergoing potentially curative resection of oesophageal cancer. World J Surg. 2011;35(8):1861–6.PubMed Dutta S, Crumley A, Fullarton G, Horgan P, McMillan D. Comparison of the prognostic value of tumour- and patient-related factors in patients undergoing potentially curative resection of oesophageal cancer. World J Surg. 2011;35(8):1861–6.PubMed
10.
go back to reference Park JH, Woodley N, McMillan DC, Glen P. Palliative stenting for oesophagogastric cancer: tumour and host factors and prognosis. BMJ Support Palliat Care. 2019;9(3):332–9.PubMed Park JH, Woodley N, McMillan DC, Glen P. Palliative stenting for oesophagogastric cancer: tumour and host factors and prognosis. BMJ Support Palliat Care. 2019;9(3):332–9.PubMed
11.
go back to reference Roxburgh C, McMillan D. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol. 2010;6(1):149–63.PubMed Roxburgh C, McMillan D. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol. 2010;6(1):149–63.PubMed
12.
go back to reference McMillan D. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39(5):534–40.PubMed McMillan D. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39(5):534–40.PubMed
13.
go back to reference Dolan RD, Lim J, McSorley ST, Horgan, PG, McMillan DC. The role of the systemic inflammatory response in predicting outcomes in patients with operable cancer: systematic review and meta-analysis. Sci Rep. 2017;7:16717.PubMedPubMedCentral Dolan RD, Lim J, McSorley ST, Horgan, PG, McMillan DC. The role of the systemic inflammatory response in predicting outcomes in patients with operable cancer: systematic review and meta-analysis. Sci Rep. 2017;7:16717.PubMedPubMedCentral
14.
go back to reference Inamoto S, Kawada K, Okamura R, Hida K, Sakai Y. Prognostic impact of the combination of neutrophil-to-lymphocyte ratio and Glasgow prognostic score in colorectal cancer: a retrospective cohort study. Int J Colorectal Dis. 2019;34:1303–15.PubMed Inamoto S, Kawada K, Okamura R, Hida K, Sakai Y. Prognostic impact of the combination of neutrophil-to-lymphocyte ratio and Glasgow prognostic score in colorectal cancer: a retrospective cohort study. Int J Colorectal Dis. 2019;34:1303–15.PubMed
15.
go back to reference Moyes L, McCaffer C, Carter R, Fullarton G, Mackay C, Forshaw M. Cardiopulmonary exercise testing as a predictor of complications in oesophagogastric cancer surgery. Ann R Coll Surg Engl. 2013;95(2):125–30. Moyes L, McCaffer C, Carter R, Fullarton G, Mackay C, Forshaw M. Cardiopulmonary exercise testing as a predictor of complications in oesophagogastric cancer surgery. Ann R Coll Surg Engl. 2013;95(2):125–30.
16.
go back to reference Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013;31(12):1539–47.PubMed Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013;31(12):1539–47.PubMed
18.
go back to reference Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–44. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–44.
20.
go back to reference Mantovani A, Ponzetta A, Inforzato A, Jaillon S. Innate immunity, inflammation and tumour progression: double-edged swords. J Intern Med. 2019;285(5):524–32.PubMedPubMedCentral Mantovani A, Ponzetta A, Inforzato A, Jaillon S. Innate immunity, inflammation and tumour progression: double-edged swords. J Intern Med. 2019;285(5):524–32.PubMedPubMedCentral
21.
go back to reference Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340(6):448–54.PubMed Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340(6):448–54.PubMed
22.
go back to reference Jaillon S, Galdiero MR, Del Prete D, Cassatella MA, Garlanda C, Mantovani A. Neutrophils in innate and adaptive immunity. Semin Immunopathol. 2013;35(4):377–94.PubMed Jaillon S, Galdiero MR, Del Prete D, Cassatella MA, Garlanda C, Mantovani A. Neutrophils in innate and adaptive immunity. Semin Immunopathol. 2013;35(4):377–94.PubMed
23.
go back to reference Park JH, Watt DG, Roxburgh CS, Horgan PG, McMillan DC. Colorectal cancer, systemic inflammation, and outcome: staging the tumor and staging the host. Ann Surg. 2016;263(2):326–36.PubMed Park JH, Watt DG, Roxburgh CS, Horgan PG, McMillan DC. Colorectal cancer, systemic inflammation, and outcome: staging the tumor and staging the host. Ann Surg. 2016;263(2):326–36.PubMed
24.
go back to reference Laird BJ, Fallon M, Hjermstad MJ, Tuck S, Kaasa S, Klepstad P, et al. Quality of life in patients with advanced cancer: differential association with performance status and systemic inflammatory response. J Clin Oncol. 2016;34(23):2769–75.PubMedPubMedCentral Laird BJ, Fallon M, Hjermstad MJ, Tuck S, Kaasa S, Klepstad P, et al. Quality of life in patients with advanced cancer: differential association with performance status and systemic inflammatory response. J Clin Oncol. 2016;34(23):2769–75.PubMedPubMedCentral
25.
go back to reference Park JH, Ishizuka M, McSorley ST, Kubota K, Roxburgh CSD, Nagata H, et al. Staging the tumor and staging the host: a two centre, two country comparison of systemic inflammatory responses of patients undergoing resection of primary operable colorectal cancer. Am J Surg. 2018;216(3):458–64.PubMed Park JH, Ishizuka M, McSorley ST, Kubota K, Roxburgh CSD, Nagata H, et al. Staging the tumor and staging the host: a two centre, two country comparison of systemic inflammatory responses of patients undergoing resection of primary operable colorectal cancer. Am J Surg. 2018;216(3):458–64.PubMed
26.
go back to reference Kurzrock R, Hickish T, Wyrwicz L, Saunders M, Wu Q, Stecher M, et al. Interleukin-1 receptor antagonist levels predict favorable outcome after bermekimab, a first-in-class true human interleukin-1α antibody, in a phase III randomized study of advanced colorectal cancer. Oncoimmunology. 2018;8(3):1551651.PubMedPubMedCentral Kurzrock R, Hickish T, Wyrwicz L, Saunders M, Wu Q, Stecher M, et al. Interleukin-1 receptor antagonist levels predict favorable outcome after bermekimab, a first-in-class true human interleukin-1α antibody, in a phase III randomized study of advanced colorectal cancer. Oncoimmunology. 2018;8(3):1551651.PubMedPubMedCentral
27.
go back to reference McDonald JJ, McMillan DC, Laird BJA. Targeting IL-1α in cancer cachexia: a narrative review. Curr Opin Support Palliat Care. 2018;12(4):453–9.PubMed McDonald JJ, McMillan DC, Laird BJA. Targeting IL-1α in cancer cachexia: a narrative review. Curr Opin Support Palliat Care. 2018;12(4):453–9.PubMed
28.
go back to reference Amaria RN, Reddy SM, Tawbi HA et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med 2018;24:1649–54.PubMedPubMedCentral Amaria RN, Reddy SM, Tawbi HA et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med 2018;24:1649–54.PubMedPubMedCentral
29.
go back to reference Forde PM, Chaft JE, Smith KN et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med 2018;378:1976–86.PubMedPubMedCentral Forde PM, Chaft JE, Smith KN et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med 2018;378:1976–86.PubMedPubMedCentral
Metadata
Title
Staging the Tumor and Staging the Host: Pretreatment Combined Neutrophil Lymphocyte Ratio and Modified Glasgow Prognostic Score Is Associated with Overall Survival in Patients with Esophagogastric Cancers Undergoing Treatment with Curative Intent
Authors
Stephen T. McSorley, PhD, MRCS
Hiu Y. N. Lau, BSc
David McIntosh, FRCP
Matthew J. Forshaw, FRCS
Donald C. McMillan, PhD
Andrew B. Crumley, MD, FRCS
Publication date
01-02-2021
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 2/2021
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-020-09074-5

Other articles of this Issue 2/2021

Annals of Surgical Oncology 2/2021 Go to the issue